9. Amended The method as claimed in claim 19, wherein the compounds are used coupled with radiolabels or with cytotoxic substances.

11. Amended The method as claimed in claim 19, wherein $R^2$ is 2,4,6 trisubstituted phenyl, in particular 2, 4, 6 triisopropyl.

Cancel claim 14 and rewrite as the following new claim:

-- 23. The method of claim 19, wherein the compound is administered orally, topically, rectally or parenterally.

Cancel claim 15 and replace by the following new claim

-- 24. The method of claim 19, wherein the compound is administered in the form of a tablet, a coated tablet, a capsule, a pellet, a suppository, a solution or transdermal system.

Amend claim 16 as follows:

16. Amended A method for inhibiting urokinase in living creatures, in particular in humans, by administering an effective quantity of at least on eurokinase inhibitor as claimed in claim 19.

Cancel claim 18 and rewrite as the following new claim

-- 25. The method of claim 19, wherein said compound is Nα (2,4,6-Triisopropylphenylsulfonyl)-3-amidino-(D,L)-phenylalanine 4-ethoxycarbonylpiperazide, an L enantiomer thereof or a pharmaceutically suitable salt thereof.

REMARKS

In response to the Restriction Requirement mailed June 24, 2002, the applicant hereby elect Group I, drawn to compounds of formula I, wherein $R^1$ contains hetero rings. This election is with traverse, as it is believed that both Group Is, namely compounds

wherein $R^1$ contains hetero rings and compounds wherein $R^1$ does not contain hetero rings should remain together, as these groups have common core members, and common utilities. Accordingly, under the PCT Rules unity of invention should be found, and withdrawal of the Restriction Requirement with respect to these groups is requested.

The Examiner required an election of a single species within the elected Group. The applicants elect the species of claim 25.

Early and favorable action on the merits is awaited.

In the event any fees are required, please charge our Deposit Account No. 01-2300.

Respectfully submitted,
Arent Fox Kintner Plotkin & Kahn, PLLC

Robert B. Murray
Registration No. 22,980

1050 Connecticut Avenue, N.W., Suite 400
Washington, D.C. 20036-5339

(202) 857-6000

RBM/cb



B

MARKED UP CLAIMS

2. The [use as claimed in claim 1] method of claim 19, [characterized in that] wherein $R^1$ is a group of the formulae (b), (d) and (f), $R^2$ represents 2, 4, 6 triisopropylphenyl, and n=0.

3. The [use as claimed in claim 1] method of claim 19, [characterized in that] wherein the compound of the formula I is

Nα-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(D,L)-phenyl-alanine 4-ethoxycarbonylpiperazide, is the L enantiomer or a pharmaceutically suitable salt of one of the compounds.

4. The [use as claimed in claim 1] method of claim 19, [characterized in that] wherein the compounds are present in the form of physiologically acceptable acid salts, in particular as hydrochlorides

8. The [use as claimed in claim 1] method as claimed in claim 19, [characterized in that] wherein the compounds of the formula I are used coupled with further pharmacologically active substances.

9. The [use as claimed in claim 8] method as claimed in claim 19, [characterized in that] wherein the compounds are used coupled with radiolabels or with cytotoxic substances.

B

11. The [use as claimed in claim 10] method as claimed in claim 19, [characterized in] wherein $R^2$ is 2,4,6 trisubstituted phenyl, in particular 2, 4, 6 triisopropyl.

16. A method for inhibiting urokinase in living creatures, in particular in humans, by administering an effective quantity of at least on eurokinase inhibitor as claimed in claim [1] 19.

B